Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

51
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
51
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

56
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
56
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

103
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
103
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

79
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
79
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

78
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
78
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

65
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence, predictors and outcomes following primary graft dysfunction after cardiac transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Three-dimensional Rotational Angiography Assessment of Symptomatic Intracranial Atherosclerotic Disease Plaque Evolution under Medical Treatment.

Radiology·2026
Same author

Cardiac implantable electronic device trends and infection risk in cardiac sarcoidosis: a 30-year perspective from southern and western Sweden.

Heart rhythm·2026
Same author

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.

Lancet (London, England)·2026
Same author

Growth patterns in patients with congenital adrenal hyperplasia analyzed by the QEPS growth model.

Frontiers in endocrinology·2026
Same author

Standardised, telemonitored titration of guideline-directed medical therapy in heart failure is associated with faster optimisation and improved persistence compared to standard of care.

Open heart·2026

Related Experiment Video

Updated: Oct 4, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.9K

Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.

Jonas Silverdal1, Helen Sjöland1, Aldina Pivodic2

  • 1Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

ESC Heart Failure
|February 8, 2022
PubMed
Summary

Patients with long-standing heart failure (HF) due to dilated cardiomyopathy (DCM) face worse outcomes than those with recent-onset HF. Comorbidities significantly impact prognosis, underscoring the need for comprehensive management in DCM patients.

Keywords:
Dilated cardiomyopathyDuration of therapyHeart failureMortalityHospitalizationCo-morbiditySystolic

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.0K

Related Experiment Videos

Last Updated: Oct 4, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.9K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.0K

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Clinical Outcomes

Background:

  • Dilated cardiomyopathy (DCM) is a significant cause of heart failure (HF).
  • Understanding prognostic factors in recent-onset versus long-standing HF in DCM is crucial for patient management.
  • The Swedish Heart Failure Registry provides a robust dataset for such investigations.

Purpose of the Study:

  • To compare outcomes between patients with recent-onset dilated cardiomyopathy heart failure (RODCM) and long-standing dilated cardiomyopathy heart failure (LDCM).
  • To identify prognostic factors associated with adverse outcomes in DCM patients with varying HF durations.

Main Methods:

  • A comparative analysis of 2019 RODCM patients and 1714 LDCM patients from the Swedish Heart Failure Registry (2003-2016).
  • Outcome measures included all-cause, cardiovascular (CV), and non-CV death, hospitalizations, heart transplantation, and a composite endpoint.
  • Multivariable risk factor and propensity score-matched analyses were employed to assess prognostic factors.

Main Results:

  • Longer disease duration (LDCM) was associated with significantly higher rates of all-cause death, CV death, heart transplantation, HF hospitalization, and a combined adverse outcome compared to RODCM.
  • Cardiovascular death was the primary cause of mortality in LDCM.
  • Comorbidities were more frequent in LDCM and increased with disease duration; diabetes was a consistent adverse factor in both groups. Male sex and aspirin use were risk factors only in RODCM, while higher heart rate, atrial fibrillation, connective tissue disorders, and diuretic use were adverse only in LDCM.

Conclusions:

  • Longer disease duration in DCM is a significant predictor of worse prognosis.
  • The increased prevalence and impact of comorbidities in LDCM highlight their importance in overall patient outcomes.
  • Effective management of comorbidities is essential for improving survival and quality of life in DCM patients, especially those with long-standing heart failure.